Dashboard
1
Flat results in Mar 26
- OPERATING CASH FLOW(Y) Lowest at CNY 322.91 MM
- INVENTORY TURNOVER RATIO(HY) Lowest at 2.38 times
- DEBTORS TURNOVER RATIO(HY) Lowest at 3.32 times
2
With ROE of 9.49%, it has a very attractive valuation with a 1.89 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,324 Million (Small Cap)
20.00
NA
1.38%
-0.44
9.49%
1.89
Revenue and Profits:
Net Sales:
380 Million
(Quarterly Results - Mar 2026)
Net Profit:
82 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.16%
0%
-7.16%
6 Months
-12.08%
0%
-12.08%
1 Year
-10.0%
0%
-10.0%
2 Years
-2.26%
0%
-2.26%
3 Years
-28.16%
0%
-28.16%
4 Years
-58.57%
0%
-58.57%
5 Years
44.0%
0%
44.0%
Jinghua Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.47%
EBIT Growth (5y)
33.16%
EBIT to Interest (avg)
61.96
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.55
Tax Ratio
15.60%
Dividend Payout Ratio
33.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.76%
ROE (avg)
7.21%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.89
EV to EBIT
14.76
EV to EBITDA
12.18
EV to Capital Employed
2.58
EV to Sales
2.77
PEG Ratio
1.44
Dividend Yield
1.38%
ROCE (Latest)
17.47%
ROE (Latest)
9.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
379.80
367.70
3.29%
Operating Profit (PBDIT) excl Other Income
87.70
71.00
23.52%
Interest
0.10
0.10
Exceptional Items
1.30
1.10
18.18%
Consolidate Net Profit
81.70
52.30
56.21%
Operating Profit Margin (Excl OI)
231.00%
137.00%
9.40%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 3.29% vs 1.88% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 56.21% vs -9.67% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,446.90
1,390.60
4.05%
Operating Profit (PBDIT) excl Other Income
346.60
299.70
15.65%
Interest
0.80
1.60
-50.00%
Exceptional Items
4.00
1.50
166.67%
Consolidate Net Profit
261.80
247.50
5.78%
Operating Profit Margin (Excl OI)
183.90%
167.00%
1.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.05% vs -7.27% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 5.78% vs -10.49% in Dec 2024
About Jinghua Pharmaceutical Group Co., Ltd. 
Jinghua Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






